Search

Displaying results 1851 - 1860 of 9314 in total
  1. Drug

    Repotrectinib

    go.drugbank.com/drugs/DB16826
    ApprovedInvestigational

    Repotrectinib is a next-generation tyrosine kinase inhibitor (TKI) specifically designed to address resistance in the treatment of non-small cell lung cancer (NSCLC), specifically due to mutations in the … [A262056] ROS1 mutations are one of the defined oncogenic drives of NSCLC, and the solvent-front mutation ROS1 G2032R is responsible for 50 to 60% of [crizotinib]-resistant cases.

  2. Drug

    Meningococcal polysaccharide vaccine group A

    go.drugbank.com/drugs/DB13889
    ApprovedInvestigational

    It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup A.

    Mixtures: NIMENRIX 0,5 ML IM ENJEKSIYON ICIN TOZ ICEREN FLAKON VE COZUCU ICEREN KULLANIMA HAZIR ENJEKTOR, 1 ADET
  3. Drug

    Methdilazine

    go.drugbank.com/drugs/DB00902
    Approved

    It is used in the treatment of various dermatoses to relieve pruritus.

  4. Drug

    Quizartinib

    go.drugbank.com/drugs/DB12874
    ApprovedInvestigational

    [A260651] Therefore, quizartinib is proven to be a beneficial addition to the current AML treatment regimen, although serious side effects such as QT prolongation necessitates further research to optimize … [A260641] Quizartinib was approved by the FDA in July 2023 and developed under the brand name VANFLYTA by Daiichi Sankyo.

  5. Drug

    Romosozumab

    go.drugbank.com/drugs/DB11866
    ApprovedInvestigational

    to other osteoperosis therapies[L9554]. … Romosozumab is marketed in the United States by Amgen under the brand name Evinity[L5921]. Romosozumab was granted FDA approval on April 9,2019[L5921].

  6. Drug

    1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol))

    go.drugbank.com/drugs/DB11331
    ApprovedWithdrawn

    The product was meant to compensate for alveolar surfactant deficiency and reduce to likelihood of alveolar collapse leading to acute respiratory collapse.

  7. Drug

    Trifluridine

    go.drugbank.com/drugs/DB00432
    ApprovedInvestigational

    The combination product of trifluridine with tipiracil marketed as Lonsurf has been approved in Japan, the United States, and the European Union for the treatment of adult patients with metastatic colorectal … It is an active antiviral agent in ophthalmic solutions used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus.

    Synonyms: F₃T
  8. Drug

    Atogepant

    go.drugbank.com/drugs/DB16098
    ApprovedInvestigational

    to other preventative therapies. … It was developed by AbbVie and received FDA approval under the brand name Qulipta in September 2021.

  9. Drug

    Elbasvir

    go.drugbank.com/drugs/DB11574
    Approved

    [synthesis] The barrier to the development of resistance to NS5A inhibitors is lower than that of NS5B inhibitors, another class of DAAs. … of SARS-CoV-2, the human coronavirus responsible for the COVID-19 pandemic.

  10. Drug

    Vibegron

    go.drugbank.com/drugs/DB14895
    ApprovedInvestigational

    Unlike mirabegron, vibegron is less likely to be associated with drug-drug interactions involving the CYP3A4, 2D6, or 2C9 enzymes.[A226065] … On December 23, 2020, vibegron was approved for the same indication in adults. It is available as oral tablets under the market name GEMTESA.